RetinalGenix Technologies Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RTGN research report →
Price Chart
About the company
RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss.
- CEO
- Jerry Katzman
- IPO
- 2022
- HQ
- Apollo Beach, FL, US
Get TickerSpark's AI analysis on RTGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $75.19M
- P/E
- -36.04
- PEG
- -1.17
- P/S
- 0.00
- P/B
- -28.42
- EV/EBITDA
- 218.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 86.41%
- ROIC
- 8.73%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-639,456-66928.9%
- Op Income
- $-2,424,590
- Net Income
- $-2,428,595+43.8%
- EPS
- $-0.13+45.8%
- OCF Growth
- +24.7%
- FCF Growth
- +24.7%
- 52W High
- $4.01
- 52W Low
- $3.20
- 50D MA
- $4.00
- 200D MA
- $3.64
- Beta
- -3.30
- RSI (14)
- 8
- Avg Volume
- 10
No earnings-call transcripts are available for RTGN yet.
- Free Float
- 33.2%
- Shares Outstanding
- 18.84M
- Float Shares
- 6.25M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 15 | Conley Richard K | other | 5,000 |
| Apr 30, 15 | Akao Akihisa | other | 5,000 |
| Mar 23, 15 | Oculus Innovative Sciences, Inc. | sell | 350,000 |
| Feb 27, 15 | Akao Akihisa | other | 0 |
| May 11, 14 | Conley Richard K | other | 58,000 |
| May 12, 14 | Conley Richard K | other | 10,000 |
| Mar 26, 14 | Oculus Innovative Sciences, Inc. | other | 0 |
| Mar 21, 14 | Conley Richard K | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RTGN coverage
Recent articles, reports, and earnings notes.
No research on RTGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RTGN report →RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
globenewswire.com · Jan 14
RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO
globenewswire.com · Dec 8
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
globenewswire.com · Oct 16
RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
globenewswire.com · Oct 1
RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
globenewswire.com · Sep 25
RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
globenewswire.com · Jun 27
RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives
globenewswire.com · Jun 13
RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
globenewswire.com · May 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.